Literature DB >> 11139346

Surgical treatment of portal hypertension.

J M Henderson1.   

Abstract

The surgical treatment of portal hypertension has laxed and waned over the past century. Decompressive shunts for variceal bleeding hit their peak in the 1970s, but dissatisfaction with encephalopathy and liver failure led to further developments with selective shunts and devascularization procedures in the 1970s and early 1980s. Liver transplant is the major operative intervention currently in use and of advantage to patients with portal hypertension. The role of the surgeon is as part of the team involved in the full evaluation of patients with cirrhosis and portal hypertension with its complications. The current repertoire of surgical options includes decompressive shunts, either total, partial or selective, devascularization procedures and liver transplantation. These options must be fitted into the overall management schema of pharmacologic and endoscopic therapy as the first-line approaches to managing these patients. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 11139346     DOI: 10.1053/bega.2000.0138

Source DB:  PubMed          Journal:  Baillieres Best Pract Res Clin Gastroenterol


  3 in total

1.  Long-term results of fundectomy and periesophagogastric devascularization in patients with gastric fundal variceal bleeding.

Authors:  Joo-Ho Lee; Ho-Seong Han; Hyun-Ah Kim; Min-Young Koo
Journal:  World J Surg       Date:  2009-10       Impact factor: 3.352

2.  Visualization of the left extraperitoneal space and spatial relationships to its related spaces by the visible human project.

Authors:  Haotong Xu; Xiaoxiao Li; Zhengzhi Zhang; Mingguo Qiu; Qiwen Mu; Yi Wu; Liwen Tan; Shaoxiang Zhang; Xiaoming Zhang
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

3.  Prognosis of patients with hepatocellular carcinoma and hypersplenism after surgery: a single-center experience from the People's Republic of China.

Authors:  Cong Li; Hong Zhao; Jianjun Zhao; Zhiyu Li; Zhen Huang; Yefan Zhang; Xinyu Bi; Jianqiang Cai
Journal:  Onco Targets Ther       Date:  2014-06-09       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.